Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash & Equivalents (2020 - 2025)

Bioventus' Cash & Equivalents history spans 6 years, with the latest figure at $51.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 23.22% year-over-year to $51.2 million; the TTM value through Dec 2025 reached $51.2 million, up 23.22%, while the annual FY2025 figure was $51.2 million, 23.22% up from the prior year.
  • Cash & Equivalents reached $51.2 million in Q4 2025 per BVS's latest filing, up from $42.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $138.1 million in Q3 2021 to a low of $22.8 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $50.3 million, with a median of $39.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 80.63% in 2021, then plummeted 78.85% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $43.9 million in 2021, then crashed by 31.29% to $30.2 million in 2022, then increased by 22.45% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Cash & Equivalents are $51.2 million (Q4 2025), $42.2 million (Q3 2025), and $32.9 million (Q2 2025).